Skip to main content

Table 4 Summary of the most commonly reported adverse events (regardless of causality and reported at any grade in ≥10 % of patients)

From: A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

n (%) All patients (N = 36) Age ≤65 years (n = 19) Age >65 years (n = 17)
All grades Grade ≥ 3 All grades Grade ≥ 3 All Grades Grade ≥ 3
Patients with ≥ 1 AE 36 (100.0) 31 (86.1) 19 (100.0) 16 (84.2) 17 (100.0) 15 (88.2)
Neutropenia 26 (72.2) 23 (63.9) 16 (84.2) 14 (73.7) 10 (58.8) 9 (52.9)
Anemia 17 (47.2) 15 (41.7) 9 (47.4) 8 (42.1) 8 (47.1) 7 (41.2)
Thrombocytopenia 17 (47.2) 11 (30.6) 11 (57.9) 6 (31.6) 6 (35.3) 5 (29.4)
Pyrexia 9 (25.0) 0 5 (26.3) 0 4 (23.5) 0
Constipation 8 (22.2) 2 (5.6) 6 (31.6) 1 (5.3) 2 (11.8) 1 (5.9)
Nasopharyngitis 8 (22.2) 0 2 (10.5) 0 6 (35.3) 0
Lymphopenia 7 (19.4) 6 (16.7) 4 (21.1) 3 (15.8) 3 (17.6) 3 (17.6)
Diarrhea 7 (19.4) 0 5 (26.3) 0 2 (11.8) 0
Nausea 7 (19.4) 0 4 (21.1) 0 3 (17.6) 0
Leukopenia 6 (16.7) 4 (11.1) 3 (15.8) 2 (10.5) 3 (17.6) 2 (11.8)
Peripheral edema 6 (16.7) 0 2 (10.5) 0 4 (23.5) 0
Rash 6 (16.7) 0 4 (21.1) 0 2 (11.8) 0
Insomnia 6 (16.7) 0 2 (10.5) 0 4 (23.5) 0
Pneumonia 5 (13.9) 3 (8.3) 1 (5.3) 0 4 (23.5) 3 (17.6)
Decreased appetite 5 (13.9) 3 (8.3) 2 (10.5) 1 (5.3) 3 (17.6) 2 (11.8)
Malaise 5 (13.9) 0 4 (21.1) 0 1 (5.9) 0
Dysgeusia 5 (13.9) 0 2 (10.5) 0 3 (17.6) 0
Hypoxia 4 (11.1) 1 (2.8) 3 (15.8) 1 (5.3) 1 (5.9) 0
Epistaxis 4 (11.1) 0 2 (10.5) 0 2 (11.8) 0
Upper respiratory tract infection 4 (11.1) 0 2 (10.5) 0 2 (11.8) 0
  1. AE adverse event